Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer - Gilde Healthcare

Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer

18 mei 2014

New Manufacturing Capabilities to Support early Development

Mads Laustsen, formerly of CMC Biologics, Joins Symphogen 1 June 2014

COPENHAGEN, Denmark: Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced the relocation of its corporate headquarters in Lyngby, outside Copenhagen, Denmark to a 10.000 m2 (100,000 ft2) facility in Ballerup, also a suburb of Copenhagen. Separately, Symphogen announced that Mads Laustsen was appointed to the newly created position of Chief Manufacturing Officer.

Mads Laustsen, one of the founders of CMC Biologics, served as the Company’s CEO from the time of the Company’s inception 2001 until May 2011, when he was named to the Board of Directors. During this period, the company grew from a business idea to a global leader in contract biologics manufacturing.  Laustsen joins Symphogen June 1, but remains a non-executive Director on the CMC Biologics Board. Prior to establishing CMC Biologics, he spent 16 years developing and manufacturing bulk enzymes and biopharmaceuticals at Novo Nordisk, Zymogenetics, and Novozymes. Laustsen has served as a member of various advisory boards, has been active in development of new process technologies, and holds numerous patents in the field.

Laustsen commented,

“Symphogen’s antibody mixtures are at the forefront of a new generation of therapeutic options for cancer patients. Equally as important, Symphogen has pioneered manufacturing processes that few believed were possible, and demonstrated capabilities and efficiencies that are now ready to advance to a much larger scale. Clearly, the company is at a crossroads in its development, and I look forward to joining its accomplished leadership team.”

Chief Executive Officer of Symphogen, Kirsten Drejer, PhD commented:

“Mads Laustsen adds extensive manufacturing experience to Symphogen’s experienced Executive Management Team, and will help transform Symphogen from a company focused on R&D to an integrated business organization with in-house antibody production capabilities.”

About Symphogen A/S

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market.

The Company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The Company has matured its oncology pipeline and has currently brought two product candidates into the clinic. The Company’s productive technology suite – capable of identifying, selecting and manufacturing optimal antibody mixtures – fuels Symphogen’s innovative pipeline.

The lead oncology product Sym004, was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.

In total, the Company has raised €249 million in equity capital from premier international investors, and employs 100 people, most of whom are based at Symphogen’s facilities in Copenhagen.

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025